Annotated Medicine and Device Lists
| List | Section | Observation |
|---|---|---|
| Guyana. Essential Medicines List. 2020-2021 | Antileishmaniasis Medicines | No observations |
| List | Section | Observation |
|---|---|---|
| WHO Model List of Essential Medicines (2021) | 6.5.2. Antileishmaniasis medicines | No observations |
| List | Section | Observation |
|---|---|---|
| Paraguay. Lista de Medicamentos Esenciales. 2009 | 01. ANTIPROTOZOARIOS | No observations |
| List | Section | Observation |
|---|---|---|
| Ecuador | Essential Medicines List - Ecuador | No observations |
| Costa Rica. Caja Costarricense de Seguro Social. 2019 | 01. Amebicidas y antihelmínticos |
Others observations: Equivalente a 85 mg/mL de antimonio pentavalente (Sb +5) o Meglumina antimoniato 300 mg/mL equivalente a 81 mg/mL de antimonio pentavalente (Sb +5) o Estibogluconato sódico 300 mg/mL equivalente a 100 mg/mL de antimonio pentavalente (Sb +5). Contiene preservante. Solución inyectable. Ampolla con 5 mL |
| El Salvador - 2019 | ANTIPROTOZOARIOS |
Others observations: USO EXCLUSIVO DE: INFECTOLOGÍA Y DERMATOLOGÍA |
| Brasil. Relação Nacional de Medicamentos Essenciais. 2020 | P. PRODUTOS ANTIPARASITARIOS, INSECTICIDAS E REPELENTES | No observations |
| Costa Rica. Caja Costarricense de Seguro Social. 2019 | 01. Amebicidas y antihelminticos | No observations |
| List | Section | Observation |
|---|---|---|
| PAHO Strategic Fund Medicine List | 2.7.1. Antileishmaniasis medicines |
Others observations: Limited supply options (normally, none or only one supplier identified / prequalified); may result in longer delivery times. |
| Peru | 6.5.2 Anti-Leishmaniasis | No observations |